Windjammer Capital Acquires Bio X Cell
December 13, 2023
Windjammer Capital Investors completed a control acquisition of Bio X Cell, a producer of monoclonal antibodies for pre-clinical research, in a transaction that closed November 6, 2023. Windjammer said it will partner with management to accelerate organic growth and pursue a thesis-driven acquisition strategy to expand Bio X Cell's addressable market.
- Buyers
- Windjammer Capital Investors
- Targets
- Bio X Cell
- Industry
- Biotechnology
- Location
- New Hampshire, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.